Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
OPKO Health, Inc. (NASDAQ: OPK) will announce its financial results for the first quarter of 2023 on May 3, 2023, after market close. The company plans to host a conference call and webcast to discuss the results and provide financial guidance at 4:30 p.m. Eastern time on the same day. Interested participants are encouraged to pre-register for the call to receive a unique PIN for immediate access. A replay of the call will be available until May 10, 2023. OPKO is focused on establishing leading positions in biopharmaceuticals and diagnostics through its proprietary technologies and expertise.
OPKO Health, Inc. (NASDAQ: OPK) has announced an R&D Day event scheduled for March 20, 2023, at 4:00 p.m. Eastern time. This two-hour virtual event will feature presentations from OPKO executives regarding ModeX Therapeutics' multispecific technology platforms, focusing on oncology and infectious diseases. Management will also discuss the MDX-2201 technology associated with a recently announced collaboration with Merck for a vaccine targeting Epstein-Barr virus. Attendees can access the live and archived webcast on OPKO’s Investor Relations website and participate in a Q&A session afterward.
OPKO Health announced an exclusive worldwide license and collaboration agreement with Merck for the development of MDX-2201, a preclinical nanoparticle vaccine targeting the Epstein-Barr virus (EBV). This vaccine aims to address the health challenges posed by EBV, including infectious mononucleosis and associated cancers. Under the agreement, OPKO will receive an upfront payment of $50 million and potential milestone payments totaling up to $872.5 million, in addition to royalties on global sales. The collaboration highlights ModeX's innovative multi-targeting approach and Merck's expertise in vaccine development.